(C) PLOS One
This story was originally published by PLOS One and is unaltered.
. . . . . . . . . .



Triple drug (IDA) mass drug administration for elimination of lymphatic filariasis [1]

[]

Date: 2022-07

Biology & Life Sciences

This collection reports results of clinical trials and community studies of the safety, efficacy, and acceptability of the triple drug regimen IDA (ivermectin plus DEC and Albendazole) as a mass drug administration (MDA) regimen for lymphatic filariasis (LF) elimination programmes. As a group, these papers provide a comprehensive record of how these linked studies helped IDA to make the transition from research discovery to policy change and implementation. Data from these studies supported WHO’s decision to endorse IDA as a tool to accelerate LF elimination in many settings, and tens of millions of people now receive IDA each year.

[END]
---
[1] Url: https://collections.plos.org/collection/triple-drug-ida-mass-drug-administration-for-elimination-of-lymphatic-filariasis/

Published and (C) by PLOS One
Content appears here under this condition or license: Creative Commons - Attribution BY 4.0.

via Magical.Fish Gopher News Feeds:
gopher://magical.fish/1/feeds/news/plosone/

You are viewing proxied material from magical.fish. The copyright of proxied material belongs to its original authors. Any comments or complaints in relation to proxied material should be directed to the original authors of the content concerned. Please see the disclaimer for more details.